help button home button The Oncologist http://theoncologist.alphamedpress.org/misc/eLetters.shtml
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mackall, C. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mackall, C. L.
The Oncologist, Vol. 4, No. 5, 370-378, October 1999
© 1999 AlphaMed Press

T-Cell Immunodeficiency Following Cytotoxic Antineoplastic Therapy: A Review

Crystal L. Mackall

Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA

Correspondence: Crystal L. Mackall, M.D., Pediatric Oncology Branch, National Cancer Institute, Bldg. 10, Rm. 13N240, 10 Center Dr., MSC 1928 Bethesda, Maryland 20892, USA. Telephone: 301-402-5940; Fax: 301-402-0575; e-mail: cm35c{at}nih.gov

Although cancer itself is immunosuppressive, cytotoxic antineoplastic therapy is the primary contributor to the clinical immunodeficiency observed in cancer patients. The immunodeficiency induced by cytotoxic antineoplastic therapy is primarily related to T-cell depletion, with CD4 depletion generally more severe than CD8 depletion. Myeloablative therapy, dose-intensive alkylating agents, purine nucleoside analogs, and corticosteroids substantially increase the risk of therapy-induced immunosuppression. Restoration of T-cell populations following cytotoxic antineoplastic therapy is a complex process. Efficient recovery of CD4+ T cell populations requires thymic-dependent pathways which undergo an age-dependent decline resulting in prolonged CD4+ T-cell depletion in adults following T-cell-depleting therapy. Total CD8+ T-cell numbers recover in both children and adults relatively quickly post-therapy; however, CD8+ subset disruptions often remain for a prolonged period. The clinical management of patients with therapy-induced T-cell depletion involves the maintenance of a high index of suspicion for opportunistic pathogens, irradiation of blood products, prophylaxis for viral infections, and reimmunization in selected clinical circumstances. Future research avenues include efforts to rapidly rebuild immunity following cytotoxic antineoplastic therapy so that immune-based therapies may be utilized immediately following cytotoxic therapy to target minimal residual neoplastic disease.

Key Words. Immunodeficiency • Thymus • T cells • Immune reconstitution




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
C. L. Mackall, E. H. Rhee, E. J. Read, H. M. Khuu, S. F. Leitman, D. Bernstein, M. Tesso, L. M. Long, D. Grindler, M. Merino, et al.
A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas
Clin. Cancer Res., August 1, 2008; 14(15): 4850 - 4858.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
H. Xue, M. B. Sawyer, C. J. Field, L. A. Dieleman, D. Murray, and V. E. Baracos
Bolus Oral Glutamine Protects Rats against CPT-11-Induced Diarrhea and Differentially Activates Cytoprotective Mechanisms in Host Intestine but Not Tumor
J. Nutr., April 1, 2008; 138(4): 740 - 746.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
C. M. El Saleeby, G. W. Somes, J. P. DeVincenzo, and A. H. Gaur
Risk Factors for Severe Respiratory Syncytial Virus Disease in Children With Cancer: The Importance of Lymphopenia and Young Age
Pediatrics, February 1, 2008; 121(2): 235 - 243.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. J. Weigel, D. A. Rodeberg, A. M. Krieg, and B. R. Blazar
CpG Oligodeoxynucleotides Potentiate the Antitumor Effects of Chemotherapy or Tumor Resection in an Orthotopic Murine Model of Rhabdomyosarcoma
Clin. Cancer Res., August 1, 2003; 9(8): 3105 - 3114.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Spisek, P. Chevallier, N. Morineau, N. Milpied, H. Avet-Loiseau, J.-L. Harousseau, K. Meflah, and M. Gregoire
Induction of Leukemia-specific Cytotoxic Response by Cross-Presentation of Late-Apoptotic Leukemic Blasts by Autologous Dendritic Cells of Nonleukemic Origin
Cancer Res., May 1, 2002; 62(10): 2861 - 2868.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl

Copyright © 1999 by AlphaMed Press.